← board
RKTO
distress 8/10 · high distress / dilution risk$0.82-1%today-63% from 52w high
Lead: EGFR inhibitor skin toxicity
Revenue
pre-revenue
Liquidity
$4M
Runway
0.4 yrs
Shares 1y
+44%
Price & events
-22.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-3.5%
1W
-20.7%
1M
+2.3%
3M
-23.0%
6M
-40.0%
1Y
-16.0%
2Y
-97.7%
5Y
-98.7%
All
Overview
- Market Cap
- $15.62M
- Volume
- 87.76K
- 52 Week Range
- $0.51 – $2.22
- Total Shares
- 19.13M
- Float Shares
- 18.57M
- Short %
- 13.75%
- % Held by Insiders
- 2.63%
- % Held by Institutions
- 3.79%
- RVOL
- 0.01x
- Beta
- 0.93
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 4
- 2026-05-28partnershipAccepted into AMD AI Developer Program for access to AI development resources, cloud computing credits, and technical training.SEC 8-K
- Q1 2026readoutPhase 2HT-001 · Full Data Set for Open Label PK CohortSEC 8-K
- Q4 2025readoutPhase 2HT-001 · Full data set for open-label PK cohort of Phase 2a trialSEC 8-K
- Q3 2025regulatory submissionFiled (NDA/BLA)HT-001 · Submission to European Medical Agency for Clinical Trial Expansion in EUSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-25D. Boral CapitalBuy
- 2026-03-04D. Boral CapitalBuy
- 2025-12-04D. Boral CapitalBuy
Competitors — EGFR inhibitor skin toxicity
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.